(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/194043 A1

(51) International Patent Classification:
A61K 47/26 (2006.01) *A61K 39/00* (2006.01)
A61K 38/00 (2006.01)

(21) International Application Number:
PCT/US2025/019942

(22) International Filing Date:
14 March 2025 (14.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/565,861 15 March 2024 (15.03.2024) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventors: **TANG, Xiaolin**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **BREYDO, Leonid**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **TANG, Michelle**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(74) Agent: **ISACSON, John, P.** et al.; Mccarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

(54) Title: POLYSORBATE AND POLYOXYETHYLENE SORBITAN AS EXCIPIENTS FOR STABLE PROTEIN FORMULATIONS




FIG. 1E

(57) Abstract: The present inventions provide hydrolyzed polysorbates and polyoxyethylene sorbitans (POES), such as isolated POES), and/or synthetic POES (sPOES), alone or in combination with one or more polysorbate types in protein formulations to provide stabilized formulations and to prevent surface absorption, degradation, and aggregation during agitation. The inventions also provide methods of making POESs and using POESs, alone or in combination with polysorbate types, in protein compositions, as well as in therapeutic and pharmaceutical formulations.

[Continued on next page]

WO 2025/194043 A1

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*